You are here
Roche drug cocktail doubles chance of holding lung cancer at bay
ADDING Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome that some experts labelled as unprecedented.
Thirty-seven per cent of patients in a closely watched clinical
CALL +65 6388 3838 EMAIL firstname.lastname@example.org